Enveric Biosciences Net Income From Continuing Ops Over Time
| ENVB Stock | USD 3.04 0.13 4.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Enveric Biosciences Performance and Enveric Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. Projected growth potential of Enveric fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enveric Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (119.64) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
Understanding Enveric Biosciences requires distinguishing between market price and book value, where the latter reflects Enveric's accounting equity. The concept of intrinsic value—what Enveric Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Enveric Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Enveric Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enveric Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Enveric Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Enveric Biosciences and related stocks such as Jasper Therapeutics, Onconetix, and ZyVersa Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JSPR | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (36.8 M) | (51.2 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| ONCO | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (3.4 M) | (13.4 M) | (37.4 M) | (58.7 M) | (52.8 M) | (50.2 M) |
| ZVSA | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (8.1 M) | (14 M) | (89.6 M) | (9.4 M) | (8.5 M) | (8.9 M) |
| INDP | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| SPRC | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (8.9 M) | (4.5 M) | (3.5 M) | (5.8 M) | (2.6 M) | (5.9 M) | (7.5 M) | (8.6 M) | (9 M) |
| AZTR | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (10.7 M) | (11.3 M) | (9 M) | (8.1 M) | (8.5 M) |
| SLXN | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (5.1 M) | (16.5 M) | (14.9 M) | (14.1 M) |
| SCNI | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (109.2 M) | (1.4 M) | (40 M) | (5.8 M) | (6.5 M) | 4.8 M | 5.5 M | 5.8 M |
Enveric Biosciences and related stocks such as Jasper Therapeutics, Onconetix, and ZyVersa Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Enveric Biosciences | ENVB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 245 First Street, |
| Exchange | NASDAQ Exchange |
USD 3.04
Check out Enveric Biosciences Performance and Enveric Biosciences Correlation. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Enveric Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.